L-JNKi1

Jnk inhibitor

This L-stereoisomer is a cell permeable JNK (c-Jun N-terminal kinase) inhibitor. For increased cell permeability the peptide was covalently linked to the 10 aa recognized by the TAT transporter. Neuroprotective agent for stroke. Inhibits the interaction between JNK (JNK-1, -2 and -3) and its substrate with the same IC $_{50}$ (in vitro IC $_{50}$ ~ 1µM), but is degraded more readily than the D-stereoisomer, thus requiring higher treatment concentrations in vitro and in vivo.

A protein inhibitor named IB1 has been described that competitively blocks the interaction between JNK and c-Jun, thereby inhibiting the signalling events downstream of JNK like c-Jun, ATF2 and ELK1 phosphorylation. To convert IB1 into cell-permeable inhibitors of JNK (JNKI peptides) the minimal 20 aa inhibitory sequence of IB1 was covalently linked to the 10 amino acids recognized by TAT transporter. The L-JNKI1 and the protease resistant D-JNKI1 peptides represent the only potent inhibitors that are specific for JNK (JNK1, JNK2 and JNK3). Different from chemical inhibitors that directly affect kinase activity e.g. by competing with the ATP-binding site of the protein kinase, JNKI1 rather inhibits the interaction between JNK and its substrate, resulting in a JNK K.O. phenotype. In contrast to pure diffusion the TAT-peptides are actively transported into cells, where they remain until their proteolytic degradation. They can be used for in vitro as well as for in vivo applications (IC50~1µM). D-JNKI1 is the only form found to be active on neuronal cells, probably due to a high level of proteolytic degradation of the L-stereoisomer (T. Borsello and C. Bonny; unpublished data).

Citations: 9

View Online »

Ordering Information

Order Online »

BML-EI354-0001 1mg

Manuals, SDS & CofA

View Online »

Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended. Stable for at least

2 years after receipt when stored at -20°C. Solutions can be stored at -20°C for up to 3

months.

Handling Avoid freeze/thaw cycles.

Long Term Storage -20°C

Shipping Blue Ice

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name JNK inhibitor 1 (L-stereoisomer), c-Jun N-terminal kinase peptide inhibitor 1, L-

stereoisomer

Appearance White to off-white solid.

 $C_{164}H_{286}N_{66}O_{40}$ **Formula**

Formulation Lyophilized.

MW 3822.5

Purity ≥95% (HPLC)

Sequence H-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Pro-Arg-Pro-Lys-Arg-Pro-Thr-Thr-Leu-

Asn-Leu-Phe-Pro-Gln-Val-Pro-Arg-Ser-Gln-Asp-NH₂

Solubility Soluble in water.

Technical Info / Product

Notes

As these peptides tend to be toxic in neurons above concentrations of 5µM, it is recommended to use concentrations of ~1µM or less. When interpreting results of c-Jun inhibition, one should also note that a number of other c-Jun kinases are thought to contribute to c-Jun phosphorylation (C. Bonny, personal communication).

For in vivo applications in mice it is suggested to start with 30-50µl of a 1mM stock solution administered intraperitoneally. Cellular uptake of L-JNKI1 peptides can now be



ENZO LIFE SCIENCES info-

& Luxembourg Phone: +32 3 466 0420

enzo life sciences**confirmed lising** the FITG-conjugated L-TAT control peptide (Prod. No. ALX-168-009F).

0845 601 1488 Phone: +44 1392 825900

uk@enzolifesciences.com

Note Property AT ** Control peptides should on property and the property of the peptides should on property of the peptides of th eu@enzolifesciences.com